Edgewood Oncology is a clinical-stage biotechnology company developing BTX-A51, a first-in-class oral small-molecule multi-kinase inhibitor that co-targets casein kinase 1 alpha (CK1α) and cyclin-dependent kinases 7 and 9 (CDK7/CDK9) - three master regulators of cancer cell survival and transcription. Founded by veteran biotech executive David N. Cook and emerging from stealth in March 2024 with $20M in Series A financing from Alta Partners, the company is advancing BTX-A51 through Phase 2a trials in relapsed/refractory acute myeloid leukemia and genetically-defined (GATA3-mutant) ER+/HER2- metastatic breast cancer.
David N. Cook, Ph.D., is the founder and CEO of Edgewood Oncology, a Boston-based virtual biotech advancing BTX-A51, a first-in-class small molecule that hits three master regulators of cancer at once (CK1 alpha, CDK7 and CDK9) to switch on programmed cell death. A chemist by training, with an A.B. from Harvard and a Ph.D. from UC Berkeley, Cook has spent roughly 30 years building venture-backed life sciences companies, helping raise more than $1 billion, leading three IPOs, orchestrating two acquisitions, and contributing to five commercialized products. He emerged Edgewood from stealth in March 2024 with a $20 million Series A led by Alta Partners.